In India and England, an AstraZeneca vaccination has been associated to a rare neurological condition

22nd June,2021

In India and England, an AstraZeneca vaccination has been associated to a rare neurological condition

In two different investigations, physicians in India and England reported that eleven people who received the AstraZeneca-Oxford Covid-19 vaccine experienced a rare neurological illness termed Guillain-Barre syndrome.

The research, which was published in the peer-reviewed medical journal Annals of Neurology, describes a rare form of Guillain-Barre syndrome that is characterised by pronounced facial paralysis. All eleven occurrences occurred in patients who had received the vaccine between 10 and 22 days prior.A regional medical institution in Kerala, India, reported seven instances after around 1.2 million people were vaccinated with the AstraZeneca Covid-19 vaccine until April 22. Within two weeks of receiving the first dose of immunisation, the cases occurred.Six of the seven patients developed areflexic quadriplegia and required mechanical ventilatory assistance, according to Boby Varkey Maramattom of Aster Medcity in Kochi, Kerala.

"The frequency of GBS was 1.4 to 10 times greater than expected for a population of this size during this time period." Furthermore, the occurrence of bilateral facial paralysis, which occurs in less than 20% of GBS patients, shows a pattern linked to vaccination," he added.In Nottingham, England, four cases were documented, with about 700,000 people receiving the same vaccine. Within three weeks of receiving the Oxford-AstraZeneca SARS-CoV-2 vaccine, these patients developed bifacial weakness and a paraesthesias variant of GBS.

"This uncommon neurological condition has previously been linked to SARS-CoV-2 infection. Intravenous immunoglobulin, oral steroids, or no treatment were provided to our patients "Department of Neurology, Nottingham University Hospitals NHS Trust, UK, said Jonathan Rhys Evans."We recommend caution for cases of bifacial weakness with paraesthesias variant GBS following SARS-CoV-2 vaccination, as well as ensuring adequate data capture of this outcome in post-vaccination surveillance programmes to assess for causality," Evans said.